Fri, August 9, 2024
[ 12:00 AM ] - WOPRAI
Mon, June 3, 2024
[ 12:00 AM ] - WOPRAI
Mon, April 8, 2024
[ 12:00 AM ] - WOPRAI
Thu, April 4, 2024
[ 12:00 AM ] - WOPRAI
Fri, December 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, November 29, 2023
[ 12:00 AM ] - WOPRAI
Thu, October 12, 2023
[ 12:00 AM ] - WOPRAI
Tue, September 5, 2023
[ 12:00 AM ] - WOPRAI
Wed, August 9, 2023
[ 12:00 AM ] - WOPRAI
Tue, July 18, 2023
[ 12:00 AM ] - WOPRAI
Thu, May 11, 2023
[ 12:00 AM ] - WOPRAI
Tue, April 25, 2023
[ 12:00 AM ] - WOPRAI
Tue, December 13, 2022
[ 12:00 AM ] - WOPRAI
Samantha Semenkow Maintained (ALLO) at Strong Buy with Increased Target to $8 on, Aug 9th, 2024
Samantha Semenkow of Citigroup, Maintained "Allogene Therapeutics, Inc." (ALLO) at Strong Buy with Increased Target from $7 to $8 on, Aug 9th, 2024.
Samantha has made no other calls on ALLO in the last 4 months.
There are 6 other peers that have a rating on ALLO. Out of the 6 peers that are also analyzing ALLO, 1 agrees with Samantha's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Benjamin Burnett of "Stifel" Maintained at Hold with Increased Target to $4.6 on, Tuesday, May 14th, 2024
These are the ratings of the 5 analyists that currently disagree with Samantha
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $14 on, Thursday, August 8th, 2024
- Matthew Biegler of "Oppenheimer" Initiated at Buy with Decreased Target to $11 on, Thursday, August 8th, 2024
- Biren Amin of "Piper Sandler" Initiated at Buy and Held Target at $11 on, Friday, May 31st, 2024
- Mark Breidenbach of "Oppenheimer" Maintained at Buy with Decreased Target to $13 on, Tuesday, May 21st, 2024
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $9 on, Thursday, May 16th, 2024
Contributing Sources